Universitè Laval

Joël Rousseau

Jacques P Tremblay

Pierre Chapdelaine

Zoe Coulombe

Zoé Coulombe

Methods and products (e.g., gRNAs, recombinant fusion proteins, frataxin targeting systems, compositions and kits) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom.

CRISPR-based methods and products for increasing frataxin levels and uses thereof

Methods and products are described related to use of the CRISPR/Cas9 system to introduce a modification into an APP gene, such as guide RNAs and recombinant proteins, for decreasing amyloid beta peptide produced by a cell. Also described are uses of such methods and products for the treatment of Alzheimer's disease and/or age-related cognitive decline in a cell from a subject in need thereof.

Reduction of amyloid beta peptide production via modification of the APP gene using the CRISPR/Cas system

Methods and products (e.g., recombinant proteins) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom.

Growing community of inventors

Québec, Canada

Joël Rousseau